Alpha 2.0
Login Register
» Articles » PMID: 24353912

Blockade of PD-1 Immunosuppression Boosts CAR T-cell Therapy

Overview
Journal Oncoimmunology
Specialty Allergy & Immunology
Date 2013 Dec 20
PMID 24353912
Citations 81
Authors
Liza B John
Michael H Kershaw
Phillip K Darcy
Affiliations
Soon will be listed here.
Abstract

The presence of an immunosuppressive microenvironment can limit the full potential of adoptive T cell immunotherapy. However, specific blockade of the PD-1 immunosuppressive pathway can significantly enhance the function of gene-modified T cells expressing a chimeric antigen receptor (CAR) leading to enhanced tumor eradication.

Citing Articles

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.

Zhu X, Xue J, Jiang H, Xue D Mol Cancer. 2024; 23(1):237.

PMID: 39443938 PMC: 11515662. DOI: 10.1186/s12943-024-02151-3.

The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies.

Dhaliwal S, Gill F, Hamid P Cureus. 2024; 16(5):e59951.

PMID: 38854249 PMC: 11162278. DOI: 10.7759/cureus.59951.

Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment-In Vitro, In Vivo and Clinical Trials Literature Review.

Szulc A, Wozniak M Cancers (Basel). 2024; 16(8).

PMID: 38672570 PMC: 11047913. DOI: 10.3390/cancers16081483.

Enhanced cellular therapy: revolutionizing adoptive cellular therapy.

Xu M, Zeng N, Liu C, Sun J, An Y, Zhang S Exp Hematol Oncol. 2024; 13(1):47.

PMID: 38664743 PMC: 11046957. DOI: 10.1186/s40164-024-00506-6.

Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.

Li Y, Sharma A, Schmidt-Wolf I Mol Cancer. 2024; 23(1):80.

PMID: 38659003 PMC: 11040940. DOI: 10.1186/s12943-023-01926-4.

References
1.
Shi H, Liu L, Wang Z . Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett. 2012; 328(2):191-7. DOI: 10.1016/j.canlet.2012.09.015. View
2.
Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View
3.
John L, Devaud C, Duong C, Yong C, Beavis P, Haynes N . Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013; 19(20):5636-46. DOI: 10.1158/1078-0432.CCR-13-0458. View
4.
Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M . Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14(10):3044-51. DOI: 10.1158/1078-0432.CCR-07-4079. View
5.
Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View